Drug intelligence / Profile preview

tioxidazole

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Tioxidazole is an antiprotozoal drug used primarily in the treatment of schistosomiasis, a parasitic disease caused by Schistosoma species. It is a thiazole derivative and acts as an antihelmintic agent. The mechanism of action involves interference with the energy metabolism of the parasite, leading to its death. Tioxidazole has been used in some countries for treating infections caused by Schistosoma haematobium and other related parasites.

Beyond the preview

Go deeper on tioxidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tioxidazole.

Explore the full profile